LearnGlossaryMarketStocksSuperinvestorsSign in

AARD

Aardvark Therapeutics, Inc. Common Stock

Healthcare · $111M market cap

Verdict

We can't put a fair value on AARD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth—?
Free cash flow growth—?
Return on invested capital-56.6%✗

Follow AARD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 10, 2026: no open-market purchases and 2 sales worth $395K. Why purchases matter

Sales

Sun Nelson

See Remarks · 2026-09-11

Sold

$321K

Sun Nelson

See Remarks · 2026-09-10

Sold

$74K

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works